Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus fulvestrant for advanced hormone receptor-positive, HER2-negative breast cancer (real-world, single-arm)
ChiCTR2100048016Phase 4Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tucidinostat and fulvestrant in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Progression-free survival. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
tucidinostatfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100048016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048016.